Vincenzo CASOLARO | Progetti

Recent studies demonstrated an overall reduction in human leukocyte antigens (HLA) class I-presented immunopeptidome in association with downregulation of antigen presentation core complex and immunoproteasome in non small cell lung cancer (NSCLC) cells following acquisition of resistance to the EGFR-TKI osimertinib (OS). Our preliminary results indicate that genetic/pharmacological inhibition of

Study objectives are: (1) To investigate the impact of HuR silencing/inhibition on the architecture and growth of 3D tumor spheroids in TKI-sensitive and TKI-resistant NSCLC cell lines; (2) To evaluate the spatial distribution of cancer cells with preserved/ablated HuR expression within co-cultured 3D spheroids, providing insights into their interactions and localization;(3) To analyse cytokine/p

"Health4.0 Platf O2rm - Piattaforma 4.0 per l'assistenza domiciliare integrata ai malati affetti da Insufficienza Respiratoria in OLT" Prog n. F/350225/05/X60 COR: 22510394

Study aim is understanding RBPs role in (1) EGFR-TKI-induced modification of immune-related proteins levels, such as CD47 and PD-L1, with consequent impact on evasion of NK cell-mediated cytotoxicity; (2) EGFR-TKI-promoted cytokine secretion and impact on EGFR-TKI-resistance acquisition, tumor cell migration and invasion. We will use sensitive/resistant NSCLC cell lines with physiological and exog